AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37323869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk STS group
Number of subjects: 1412
Study 37323869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk STS group
Number of subjects: 1412
Study 37323869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk STS group
Number of subjects: 1412
Study 37323869 — intervention group
Group type: COMPARATOR
Intervention: Asian population
Number of subjects: 1412
Study 37323869 — intervention group
Group type: COMPARATOR
Intervention: Non-Asian population
Number of subjects: 1412
Study 37324125 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 258
Study 37324125 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 258
Study 37324410 — intervention group
Group type: EXPERIMENTAL
Intervention: Afterload-related cardiac performance (ACP)
Number of subjects: 290
Study 37324410 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected cardiac output-systemic vascular resistance (CO-SVR) curve model
Number of subjects: 290
Study 37324622 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-app (smartphone app with alarm for drug intake, visual confirmation of drug administration, medication intake history)
Number of subjects: 1042
Study 37324622 — intervention group
Group type: COMPARATOR
Intervention: Usual care (conventional treatment)
Number of subjects: 1042
Study 37324622 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-app
Number of subjects: 1042
Study 37324622 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1042
Study 37324629 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with ARD history
Number of subjects: 207
Study 37324629 — intervention group
Group type: COMPARATOR
Intervention: Women without ARD history
Number of subjects: 207
Study 37325226 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced External Counter Pulsation (EECP) therapy
Number of subjects: 0
Study 37325226 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37325351 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care-associated primary bloodstream infections (BSIs)
Number of subjects: 494
Study 37325351 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected gestational age <28 weeks at infection
Number of subjects: 494
Study 37325351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal growth restriction (FGR)
Number of subjects: 494
Study 37325351 — intervention group
Group type: EXPERIMENTAL
Intervention: Proven pathogen-related BSIs
Number of subjects: 494
Study 37325351 — intervention group
Group type: EXPERIMENTAL
Intervention: One positive blood culture
Number of subjects: 494
Study 37325398 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term low-saturated fat diet
Number of subjects: 0
Study 37325398 — intervention group
Group type: COMPARATOR
Intervention: High-saturated fat diet
Number of subjects: 0
Study 37325545 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q)
Number of subjects: 0
Study 37325545 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
Number of subjects: 0
Study 37325545 — intervention group
Group type: EXPERIMENTAL
Intervention: A-IADL-Q and ADCS-ADL
Number of subjects: 0
Study 37325628 — intervention group
Group type: EXPERIMENTAL
Intervention: In-stent restenosis (ISR) patients
Number of subjects: 60
Study 37325662 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac
Number of subjects: 270
Study 37325662 — intervention group
Group type: COMPARATOR
Intervention: Control (23-valent pneumococcal polysaccharide vaccine and inactivated hepatitis A vaccine)
Number of subjects: 270
Study 37325662 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 270
Study 37325860 — intervention group
Group type: EXPERIMENTAL
Intervention: afamitresgene autoleucel (afami-cel) therapy after low-dose radiotherapy (LDRT) at 5.6 Gy/4 fractions to the liver
Number of subjects: 1
Study 37325860 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose radiotherapy (LDRT)
Number of subjects: 1
Study 37325931 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Conservation Surgery (BCS)
Number of subjects: 1462
Study 37325931 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1462
Study 37325931 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative receptor subtype
Number of subjects: 1462
Study 37325931 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Cancer Burden (RCB) class
Number of subjects: 1462
Study 37326265 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support strategies, such as counselling and emergency preparedness training
Number of subjects: 14
Study 37326265 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study 37326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscope
Number of subjects: 1417
Study 37326325 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 1417
Study 37326322 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (1.62% daily, adjusted to maintain testosterone levels between 350 and 750 ng/dL)
Number of subjects: 5246
Study 37326322 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 5246
Study 37326322 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (1.62% daily)
Number of subjects: 5246
Study 37326371 — intervention group
Group type: EXPERIMENTAL
Intervention: Total transfemoral access (TFA)
Number of subjects: 68
Study 37326473 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of meropenem
Number of subjects: 607
Study 37326473 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of meropenem
Number of subjects: 607
Study 37326562 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenstrual phase
Number of subjects: 38
Study 37326562 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteal phase
Number of subjects: 38
Study 37326562 — intervention group
Group type: EXPERIMENTAL
Intervention: Midfollicular phase
Number of subjects: 38
Study 37326562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle phase predictors
Number of subjects: 38
Study 37326645 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 367
Study 37326645 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 367
Study 37326674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia (FM) group
Number of subjects: 15
Study 37326674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia (FM) group (high-affinity binders)
Number of subjects: 15
Study 37326674 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 15
Study 37326678 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile fibromyalgia (JFM) group
Number of subjects: 66
Study 37326678 — intervention group
Group type: COMPARATOR
Intervention: Healthy adolescent girls (control group)
Number of subjects: 66
Study 37326854 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg IV
Number of subjects: 17
Study 37326854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 37326854 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 17
Study 37326942 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR2285 (25-600 mg single ascending doses)
Number of subjects: 103
Study 37326942 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR2285 (100-400 mg multiple ascending doses)
Number of subjects: 103
Study 37326942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 37327026 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based Joviality positive psychological intervention
Number of subjects: 84
Study 37327026 — intervention group
Group type: COMPARATOR
Intervention: Sham VR (2D wildlife footage and nature-based settings with inert music)
Number of subjects: 84
Study 37327046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccination status (index test)
Number of subjects: 1361
Study 37327046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccination status at telephone follow-up
Number of subjects: 1361
Study 37327046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccination status at index ED visit
Number of subjects: 1361
Study 37327046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported number of doses
Number of subjects: 1361
Study 37327046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported brand of the first dose
Number of subjects: 1361
Study 37327046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported brand of the second dose
Number of subjects: 1361
Study 37327046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported brand of the third dose
Number of subjects: 1361
Study 37327113 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 10 mg/m2 IV on days 1, 8, and 15 plus lenalidomide 25 mg orally from days 1 to 21 of a 28-day cycle for up to 1 year
Number of subjects: 29
Study 37327113 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin plus lenalidomide
Number of subjects: 29
Study 37327216 — intervention group
Group type: EXPERIMENTAL
Intervention: Female healthcare workers
Number of subjects: 4165
Study 37327216 — intervention group
Group type: COMPARATOR
Intervention: Male healthcare workers
Number of subjects: 4165
Study 37327216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 4165
Study 37327216 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare workers expressing ITL
Number of subjects: 4165
Study 37327230 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanoid robot Pepper used at home by children with cochlear implants and their families for 1 month.
Number of subjects: 10
Study 37327319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavituximab
Number of subjects: 33
Study 37327369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Azithromycin
Number of subjects: 0
Study 37327369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Doxycycline
Number of subjects: 0
Study 37327369 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37327372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening education
Number of subjects: 0
Study 37327372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 37327382 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming
Number of subjects: 90
Study 37327382 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive warming
Number of subjects: 90
Study 37327382 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 37327461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dato-DXd 6 mg/kg once every 3 weeks
Number of subjects: 210
Study 37327468 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib
Number of subjects: 0
Study 37327468 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37327527 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (therapeutic doses)
Number of subjects: 298
Study 37327673 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype 1
Number of subjects: 382
Study 37327673 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype 2
Number of subjects: 382
Study 37327673 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype 3
Number of subjects: 382
Study 37327673 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype 4
Number of subjects: 382
Study 37327677 — intervention group
Group type: EXPERIMENTAL
Intervention: emtricitabine-tenofovir disoproxil fumarate (F/TDF) or emtricitabine-tenofovir alafenamide (F/TAF) given as a double dose once either 5 or 21 hours before ex vivo HIV-challenge.
Number of subjects: 144
Study 37327677 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 144
Study 37327809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 960 mg for 1 day
Number of subjects: 512
Study 37327809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 960 mg for 2 days
Number of subjects: 512
Study 37327809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 960 mg for 3 days
Number of subjects: 512
Study 37327809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide 800 mg plus lumefantrine-SDF 960 mg for 1 day
Number of subjects: 512
Study 37327809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide 200 mg plus lumefantrine-SDF 480 mg for 3 days
Number of subjects: 512
Study 37327809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 480 mg for 3 days
Number of subjects: 512
Study 37327809 — intervention group
Group type: COMPARATOR
Intervention: Artemether plus lumefantrine for 3 days (control)
Number of subjects: 512
Study 37327809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaplacide 400 mg plus lumefantrine-SDF 960 mg once daily for 3 days in children
Number of subjects: 512
Study 37327809 — intervention group
Group type: COMPARATOR
Intervention: Artemether plus lumefantrine for 3 days (control in children)
Number of subjects: 512
Study 37327883 — intervention group
Group type: EXPERIMENTAL
Intervention: National Early Warning Score 2 (NEWS2) with cutoff ≥5
Number of subjects: 848
Study 37327883 — intervention group
Group type: COMPARATOR
Intervention: Bova score with cutoff >4
Number of subjects: 848
Study 37327883 — intervention group
Group type: EXPERIMENTAL
Intervention: National Early Warning Score 2 (NEWS2)
Number of subjects: 848
Study 37327955 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven HRF estimation approach
Number of subjects: 0
Study 37327980 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary plaque rupture (PR)
Number of subjects: 297
Study 37327980 — intervention group
Group type: COMPARATOR
Intervention: Coronary plaque erosion (PE)
Number of subjects: 297
Study 37328176 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised breathing advice guided by visual biofeedback from the laryngoscope video screen after EILO diagnosis verification.
Number of subjects: 120
Study 37328178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based walking intervention (50 minutes, three times per week for 12 weeks)
Number of subjects: 20
Study 37328287 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-6R therapy (tocilizumab or sarilumab)
Number of subjects: 92
Study 37328392 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9™ drug coated balloon (BA9-DCB)
Number of subjects: 201
Study 37328392 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-coated SeQuent® Please DCB
Number of subjects: 201
Study 37328522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 152
Study 37328522 — intervention group
Group type: COMPARATOR
Intervention: IV ceftriaxone
Number of subjects: 152
Study 37328712 — intervention group
Group type: EXPERIMENTAL
Intervention: Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam)
Number of subjects: 36
Study 37328712 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 12)
Number of subjects: 36
Study 37328731 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Delivery Application (SDA) installed on smartphones, with half a day of introduction to the app.
Number of subjects: 176
Study 37328731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 176
Study 37328736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 37328736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 37328736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (LDL-C < 25 mg/dL)
Number of subjects: 18924
Study 37328736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (LDL-C < 25 mg/dL)
Number of subjects: 18924
Study 37328736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (LDL-C < 15 mg/dL)
Number of subjects: 18924
Study 37328736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (LDL-C < 15 mg/dL)
Number of subjects: 18924
Study 37328751 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behaviour therapy (CaCBT)
Number of subjects: 390
Study 37328751 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted family intervention (CulFI)
Number of subjects: 390
Study 37328751 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 390
Study 37328761 — intervention group
Group type: EXPERIMENTAL
Intervention: RTEL1 ultra-rare variants
Number of subjects: 2246
Study 37328797 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB group (n=64): 16 weeks of exercise training plus the BCE programme
Number of subjects: 184
Study 37328797 — intervention group
Group type: EXPERIMENTAL
Intervention: EXER group (n=65): exercise training and health talks
Number of subjects: 184
Study 37328797 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=55): only health talks
Number of subjects: 184
Study 37328810 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Navigation (FN) intervention
Number of subjects: 28
Study 37328813 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle-promoting practice implementation
Number of subjects: 27
Study 37328817 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral block
Number of subjects: 82
Study 37328817 — intervention group
Group type: COMPARATOR
Intervention: Erector Spinae Plane Block
Number of subjects: 82
Study 37328817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 82
Study 37328835 — intervention group
Group type: COMPARATOR
Intervention: Full dose gemcitabine (Gem)
Number of subjects: 100
Study 37328835 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose gemcitabine and nab-paclitaxel (GemNab)
Number of subjects: 100
Study 37328839 — intervention group
Group type: EXPERIMENTAL
Intervention: Numen Coil
Number of subjects: 124
Study 37328839 — intervention group
Group type: COMPARATOR
Intervention: Axium Coil
Number of subjects: 124
Study 37328855 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) at 220 kHz with systemically administered microbubbles, administered in three successive procedures at 2 week intervals.
Number of subjects: 8
Study 37328859 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg)
Number of subjects: 30
Study 37328859 — intervention group
Group type: COMPARATOR
Intervention: No calcium supplementation (Control)
Number of subjects: 30
Study 37328890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg IV infusion
Number of subjects: 93
Study 37328890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab 2000 mg IV infusion
Number of subjects: 93
Study 37328890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab (dosing intervals to be defined)
Number of subjects: 93
Study 37328890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 37328931 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 0.1 mg
Number of subjects: 320
Study 37328931 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 0.2 mg
Number of subjects: 320
Study 37328931 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 0.4 mg
Number of subjects: 320
Study 37328931 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide (all doses pooled)
Number of subjects: 320
Study 37328931 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 320
Study 37329220 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year lifestyle intervention
Number of subjects: 421
Study 37329220 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 421
Study 37329361 — intervention group
Group type: EXPERIMENTAL
Intervention: Three preoperative intravitreal (IVI) aflibercept injections with a monthly interval; the third injection was given intra-operatively (Group A)
Number of subjects: 40
Study 37329361 — intervention group
Group type: COMPARATOR
Intervention: Single intra-operative injection and two post-operative injections with a monthly interval (Group B)
Number of subjects: 40
Study 37329412 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization-first (EVR-1st) strategy
Number of subjects: 157
Study 37329415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab and etesevimab (BAM + ETE) - open-label weight-based dosing (WBD, n=94)
Number of subjects: 128
Study 37329415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab and etesevimab (BAM + ETE) - treated adolescent participants (n=20)
Number of subjects: 128
Study 37329415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 128
Study 37329415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab and etesevimab (BAM + ETE) - overall pediatric population (n=128)
Number of subjects: 128
Study 37329423 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM+ERL
Number of subjects: 56
Study 37329423 — intervention group
Group type: COMPARATOR
Intervention: ERL+PBO
Number of subjects: 56
Study 37329468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Disturbance Numerical Rating Scale (SD NRS)
Number of subjects: 21
Study 37329633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chios Mastiha Essential Oil (CMEO) 200 mg daily for 3 months
Number of subjects: 94
Study 37329655 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation stretching
Number of subjects: 24
Study 37329655 — intervention group
Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 24
Study 37329785 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPostC) - four cycles of 5-min inflation to a pressure of 200 mmHg followed by 5 min of deflation on healthy upper limbs once a day for 30 days.
Number of subjects: 132
Study 37329785 — intervention group
Group type: COMPARATOR
Intervention: Control group (shame) - patients' diastolic BP followed by 5 min of deflation on healthy upper limbs once a day for 30 days.
Number of subjects: 132